Home > Healthcare > Medical Devices > Therapeutic Devices > Cardiac Resynchronisation Therapy (CRT) Devices Market

Cardiac Resynchronisation Therapy (CRT) Devices Market Share

Report ID: GMI4589
Published Date: Nov 2023
Report Format: PDF

Download Free Sample

Cardiac Resynchronisation Therapy Devices Market Share

The cardiac resynchronisation therapy devices industry is consolidated in nature, with companies competing to offer superior cardiac resynchronisation therapy devices in this business space. Prominent players such as Medtronic plc, Boston Scientific Corporation, and Abbott hold a significant share in this market. These companies are diligently directing their efforts towards continuous type innovation to gain substantial market share.

Some of the eminent market participants operating in the cardiac resynchronisation therapy devices industry include:

Medtronic PLC
Abbott Laboratories
Biotronik
Boston Scientific Corporation
Microport Scientific Corporation
Medico S.p.A
LivaNova PLC

Authors: Mariam Faizullabhoy , Gauri Wani

Frequently Asked Questions (FAQ) :

The market size forcardiac resynchronisation therapy devices was valued at around USD 3.2 billion in 2022 and will reach over USD 5.6 billion by 2032, backed by the rising incidence of cardiovascular disorders, growing geriatric population, and increasing advancements in product technology.

The CRT-defibrillators segment garnered around USD 2.6 billion in 2022 and is expected to foresee a healthy growth attributed to less invasive implantation procedures, continuous advancements in pacemaker technology, and heightened awareness among both patients and healthcare providers.

The U.S. cardiac resynchronisation therapy devices market is anticipated to reach more than USD 2 billion by 2032, attributed to the presence of key industry players, increasing demand for cardiovascular devices, and the growing geriatric population in the nation.

Medtronic PLC, Abbott Laboratories, Biotronik, Boston Scientific Corporation, Microport Scientific Corporation, Medico S.p.A, and LivaNova PLC among others.